Ethel Weld, MD

Protocol chair, IMPAACT 2005
Protocol vice-chair, IMPAACT 2022
Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
Member, Pharmacology Core, HPTN Laboratory Core
Member, TB in Pregnancy Working Group
Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Johns Hopkins University Baltimore-India Clinical Trials Unit